Healthcare

Image

Asia-Pacific Clinical Trial Imaging Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Published Report
  • Sep 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 173
  • No of Figures: 44

Asia-Pacific Clinical Trial Imaging Market, By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales) - Industry Trends and Forecast to 2029.

Clinical Trial Imaging Market

Asia-Pacific Clinical Trial Imaging Market Analysis and Insights

The increasing demand for imaging technology, followed by rise in the prevalence of chronic diseases due to rise in elderly population and strategic initiatives by market players such as product launch, advancement, acquisition and agreements are the factors that are expected to drive the market growth.

Clinical Trial Imaging Market

Clinical Trial Imaging Market

However, improper and unfavourable reimbursement scenarios for imaging devices and lack of well-defined standards in clinical trial imaging instruments are expected to restrain the market growth.

The rising technological progressions in clinical trial imaging for diagnosis and treatment of chronic diseases are expected to drive market growth. Data Bridge Market Research analyzes that the Asia-Pacific clinical trial imaging market will grow at a CAGR of 8.8% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisable to 2019-2014)

Quantitative Units

Revenue in USD Million and Pricing in USD

Segments Covered

By Product and Services (Services and Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Echocardiography, Nuclear Medicine, Positron Emission Tomography, X-ray, Ultrasound, Optical Coherence Tomography and Others), Application (Oncology, Neurology, Endocrinology, Cardiology, Dermatology, Hematology and Others), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturers, Academic and Government Research Institutes and Others), Distributor (Direct Sales and Tender Sales)

Countries Covered

China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific

Market Players Covered

Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group and Invicro.LLC among others

Market Definition

Clinical trial is a process of developing new drugs. It is designed for potential treatment and its effects on humans. Before the commercialization of new drugs, extensive clinical testing is done to identify promising compounds and safety tests are conducted to determine the possible risks.

In clinical trials, medical imaging plays a significant role in more accurate and effective results. Different imaging technologies may be used to elucidate and demonstrate the mechanistic actions of drugs. Clinical trial imaging is the process of clinical analysis and medical intervention by creating image representations of inner parts of the body. It has several different technologies which are used to view the human body to monitor, treat and diagnose medical conditions.

In the coming future, important decisions related to clinical trial imaging on drug discovery will be made by individuals who not only understand the biopsy but can also use the clinical trial imaging tools and the knowledge they release to develop hypotheses and identify quality targets.

Asia-Pacific Clinical Trial Imaging Market Dynamics

Drivers

  • Rising R&D Expenditure

Imaging and pharma companies are continuously investing in R&D to offer innovative services for clinical trial imaging to customers and enhance their market presence. Medical imaging plays a dynamic role in clinical development. While the medical imaging industry is in a constant state of fluctuation due to implementation of new technologies in the market, the pharmaceutical and imaging industries continue to increase. This is attributed to enhanced investment in medical imaging companies along with mergers and acquisitions as well as the adoption of innovation in imaging technologies to support clinical trials for medical devices. Increasing R&D expenditure in pharmaceutical and biotechnological companies is fuelling market growth.

This has encouraged the development of new products and high research-oriented programs organized in biopharmaceutical industries and a high preference for the studies of human genome. Rising expenditure on R&D activities also develops new drugs and therapies to treat chronic diseases that boost market growth. This helps the pharmaceutical and biotechnological companies in the development of new technologies in the category of imaging clinical trials therefore, rising R&D expenditure is expected to drive the market growth.

  • Increasing Number of Contract Research Organizations (CROs)

Contract Research Organization (CRO) is an organization that gives support for clinical trials and other research services to imaging and pharmaceutical industries in the form of outsourced pharmaceutical research services in terms of both drugs and medical devices. CRO helps imaging and pharmaceutical industries with the drug development process to reduce the cost and initiate the process of bringing clinical trials to develop the drug for a particular disease segment by using clinical trial imaging and other processes to overcome capacity gaps of the in-house research team for pharmaceutical and clinical research.

A huge number of CROs are engaged in monitoring the drug development process such as PAREXEL (U.S.), PRA Health Sciences (U.S.), Labcorp (U.S.), PPD (U.S.), Syneos Health (U.S.), ICON plc (Ireland), Envigo (U.K.), Charles River (U.S.) and SGS (Switzerland) among others. These are some CROs that are engaged to give support for clinical trials and other research services to the imaging and pharmaceutical industries. The increasing number of CROs is expected to drive market growth.

Opportunities

  • Rise in Healthcare Expenditure

Healthcare expenditure has increased across the world as people's disposable income in various countries is increasing. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative by virtue of accelerating healthcare expenditure.

For instance,

  • National Health Expenditure Accounts (NHEA) published a report which stated that the U.S. healthcare expenditure grew by 4.6% in 2019. This estimates USD 3.80 trillion for the overall U.S. population reported by U.S. Centers for Medicare (CMS) and GDP health, spending in the U.S. is accounted to reach 17.7%.

Growing healthcare expenditure is also beneficial for further growth in the economic and healthcare sector and it is primarily fruitful as it significantly affects the development of better and advanced medical products in the market. Therefore, the surge in healthcare expenditure is expected to create a greater opportunity for the market.

  • Strategic Initiatives by Market Players

The demand for clinical trial imaging is increasing in the market owing to the increased levels of R&D along with the growth of clinical trial imaging market aided by the desire for innovative medications. Thus, the top market players have implemented a new strategy by developing new products and collaborating with other market players to improve business operations and profitability.

For instance,

  • In February 2020, ICON plc acquired MedPass International, a European medical devices CRO, reimbursement and regulatory consultancy. This acquisition has reportedly helped in the expansion of the medical device and diagnostic research services of ICON in Europe.

These strategic initiatives by the market players, including acquisition, conferences and focused segment product launches, are helping them grow and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players may act as an opportunity for market growth.

Restraints/Challenges

  • High-Risk Radiation Causing Diseases

In clinical medical imaging, radiation is absorbed by the body which can harm molecular structures inside the patient’s body. High doses of radiation can affect human cells including loss of hair, skin burns and increased incidence of cancer. The estimated risk of developing fatal cancer is one in 2000 after going through a radiation dose of 10 mSv in a CT scan.

For instance,

  • According to Radiological Society of America (RSNA), 1% to 2% of all cancers in the U.S. are caused by CT scans and the American Cancer Society identified CT scans and X-rays as one of the reasons for breast cancer, brain cancer and other cancers
  • According to the Center for Disease Control and Prevention, exposure to high levels of radiation results in acute radiation syndrome. The amount of radiation that a person's body absorbs is called the radiation dose.

The high-risk radiation that occurs, would decrease the usage and sale of clinical trial imaging devices, thereby affecting the credibility of manufacturers involved in this market. Therefore, the high-risk radiation-causing diseases are expected to restrain the market growth.

  • Strict Regulatory Policies

The healthcare industry is regulated by a structure of laws, rules & regulations that are extensive and complex.

For instance,

  • In April 2018, the U.S. FDA released updated Guidance for Clinical Trial Imaging Endpoint Process Standards for the industry which includes the quality of imaging data obtained in clinical trials
  • Biotechnology and pharmaceutical industries need to take first approval from the FDA for the process of drug development. They have to submit an Investigational New Drug (IND) application to the FDA before beginning clinical research.

COVID-19 Impact on the Asia-Pacific Clinical Trial Imaging Market

Diagnostic imaging services have been time-consuming and complicated by the need for strict infection control and prevention practices developed to contain the risk of transmission and protect healthcare personnel. Hence, the decision to image suspected patients or COVID-19-positive patients is based on their impact on the improvement of patient status. There have definitely been reduced volumes in outpatient medical imaging clinics due to social distancing regulations and lockdowns in Asia-Pacific region. This reduced the available appointments which led to longer waiting lists for exams such as ultrasound and interventional procedures.

Recent Developments

  • In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and Positron Emission Tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China.
  • In November 2021, Clario was formed. ERT and Bioclinica, merged to form Clario. The formation of a new company resulted in the distribution of clinical imaging software and services and rise in sales.

Asia-Pacific Clinical Trial Imaging Market Scope

Asia-Pacific clinical trial imaging market is segmented into five segments based on product and services, modality, application, end user and distributor. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

  • Services
  • Software

Based on product and services, the market is segmented into services and software.

Modality

  • Computed Tomography
  • Magnetic Resonance Imaging
  • Echocardiography
  • Nuclear Medicine
  • Positron Emission Tomography
  • X-ray
  • Ultrasound
  • Optical Coherence Tomography
  • Others

Based on modality, the market is segmented into computed tomography, magnetic resonance imaging, echocardiography, nuclear medicine, positron emission tomography, X-ray, ultrasound, optical coherence tomography and others.

Application

  • Oncology
  •  Neurology
  •  Cardiology
  •  Endocrinology
  •  Dermatology
  •  Hematology
  •  Others

Based on application, the market is segmented into oncology, neurology, cardiology, endocrinology, dermatology, hematology and others.

End user

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Medical Device Manufacturers
  • Academic and Government Research Institutes
  • Others

Based on end user, the market is segmented into contract research organizations, pharmaceutical & biotechnology companies, medical device manufacturers, academic and government research institutes and others.

Distributor

  • Direct Sales
  •  Tender Sales

Clinical Trial Imaging Market

Based on distributor, the market is segmented into direct sales and tender sales.

Asia-Pacific Clinical Trial Imaging Market Regional Analysis/Insights

Asia-Pacific clinical trial imaging market is analyzed and market size insights and trends are provided by regions, product and services, modality, application, end user and distributor as referenced above.

The countries covered in this market report are China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific. China is expected to dominate the market since clinical imaging is safe and convenient to use. The vital role of the government of China in setup and establishing domestic vendors in the diagnostic imaging space in China is one of the major factors expected to drive market growth.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Clinical Trial Imaging Market Share Analysis

Asia-Pacific clinical trial imaging market competitive landscape provides details on the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, the Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth and application dominance. The above data points provided are only related to the companies' focus related to the Asia-Pacific clinical trial imaging market.

Some of the major players operating in the market are Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, Perspectum, Calyx, WIRB-Copernicus Group and Invicro.LLC among others.


SKU-

TABLE 1 COST OF CLINICAL TRIAL PHASE 2 AND PHASE 3

TABLE 2 HUGE R&D COST IN THE U.S. FOR DIFFERENT PHASES

TABLE 3 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCTS & SERVICES, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC SOFTWARE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC COMPUTED TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC MAGNETIC RESONANCE IMAGING IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC ECHOCARDIOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC NUCLEAR MEDICINE IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC POSITRON EMISSION TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC X-RAY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC ULTRASOUND IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC OPTICAL COHERENCE TOMOGRAPHY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 20 ASIA PACIFIC NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 ASIA PACIFIC NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 22 ASIA PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 ASIA PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 24 ASIA PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 ASIA PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 26 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 ASIA PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 28 ASIA PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 ASIA PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 30 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 ASIA PACIFIC CONTRACT RESEARCH ORGANIZATION IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 ASIA PACIFIC PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 ASIA PACIFIC MEDICAL DEVICE MANUFACTURERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 ASIA PACIFIC ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 ASIA PACIFIC OTHERS IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 ASIA PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 38 ASIA PACIFIC DIRECT SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 ASIA PACIFIC TENDER SALES IN CLINICAL TRIAL IMAGING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 41 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 42 ASIA-PACIFIC SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 43 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 44 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 45 ASIA-PACIFIC ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 46 ASIA-PACIFIC NEUROLOGY CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 ASIA-PACIFIC ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION,2020-2029 (USD MILLION)

TABLE 48 ASIA-PACIFIC CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 ASIA-PACIFIC DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 ASIA-PACIFIC HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 53 CHINA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 54 CHINA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 55 CHINA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 56 CHINA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 57 CHINA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 58 CHINA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 59 CHINA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 60 CHINA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 61 CHINA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 CHINA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 CHINA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 CHINA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 65 JAPAN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 66 JAPAN SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 67 JAPAN CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 68 JAPAN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 69 JAPAN ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 70 JAPAN NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 71 JAPAN ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 72 JAPAN CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 JAPAN DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 74 JAPAN HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 75 JAPAN CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 JAPAN CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 77 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 78 SOUTH KOREA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 79 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 80 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 SOUTH KOREA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 82 SOUTH KOREA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 83 SOUTH KOREA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 SOUTH KOREA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 85 SOUTH KOREA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 86 SOUTH KOREA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 87 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 SOUTH KOREA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 89 INDIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 90 INDIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 91 INDIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 92 INDIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 93 INDIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 94 INDIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 INDIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 96 INDIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 97 INDIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 98 INDIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 99 INDIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 INDIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 101 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 102 AUSTRALIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 103 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 104 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 105 AUSTRALIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 106 AUSTRALIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 107 AUSTRALIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 108 AUSTRALIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 109 AUSTRALIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 110 AUSTRALIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 111 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 112 AUSTRALIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 113 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 114 SINGAPORE SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 115 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 116 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 SINGAPORE ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 118 SINGAPORE NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 119 SINGAPORE ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 120 SINGAPORE CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 121 SINGAPORE DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 122 SINGAPORE HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 123 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 124 SINGAPORE CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 125 THAILAND CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 126 THAILAND SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 127 THAILAND CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 128 THAILAND CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 129 THAILAND ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 130 THAILAND NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 131 THAILAND ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 132 THAILAND CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 133 THAILAND DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 134 THAILAND HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 135 THAILAND CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 136 THAILAND CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 137 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 138 MALAYSIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 139 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 140 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 141 MALAYSIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 142 MALAYSIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 143 MALAYSIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 144 MALAYSIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 145 MALAYSIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 146 MALAYSIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 147 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 148 MALAYSIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 149 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 150 INDONESIA SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 151 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 152 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 153 INDONESIA ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 154 INDONESIA NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 155 INDONESIA ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 156 INDONESIA CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 157 INDONESIA DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 158 INDONESIA HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 159 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 160 INDONESIA CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 161 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 162 PHILIPPINES SERVICES IN CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

TABLE 163 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2020-2029 (USD MILLION)

TABLE 164 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 165 PHILIPPINES ONCOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 166 PHILIPPINES NEUROLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 167 PHILIPPINES ENDOCRINOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 168 PHILIPPINES CARDIOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 169 PHILIPPINES DERMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 170 PHILIPPINES HEMATOLOGY IN CLINICAL TRIAL IMAGING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 171 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 172 PHILIPPINES CLINICAL TRIAL IMAGING MARKET, BY DISTRIBUTOR, 2020-2029 (USD MILLION)

TABLE 173 REST OF ASIA-PACIFIC CLINICAL TRIAL IMAGING MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Asia-Pacific Clinical Trial Imaging Market is anticipated to reach a CAGR of 8.8% forecast by 2029.
Asia-Pacific Clinical Trial Imaging Market is segmented on the basis of product & services, modality, application & distributor.
The major players in the Asia-Pacific Clinical Trial Imaging Market are Navitas Life Sciences, Resonance Health Analytical Services, ICON plc, Image Core Lab, Radiant Sage LLC, WORLDCARE CLINICAL, Clario, Paraxel International Corporation, Median Technologies, etc.
China is expected to dominate the market since clinical imaging is safe and convenient to use.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials